{"log_id": 4451551578054960421, "direction": 0, "words_result_num": 41, "words_result": [{"probability": {"variance": 1.7e-05, "average": 0.997222, "min": 0.982126}, "location": {"width": 796, "top": 156, "height": 32, "left": 240}, "words": "利奈唑胺上市后的临床应用中,有骨髓抑制报道(包括贫血、白细胞减少、全血细胞减少和"}, {"probability": {"variance": 0.000304, "average": 0.994108, "min": 0.89453}, "location": {"width": 795, "top": 188, "height": 27, "left": 241}, "words": "血小板减少)(见警告)。曾有周围神经病和视神经病变有时进展至失明的报道。应用利奈唑"}, {"probability": {"variance": 0.004296, "average": 0.987557, "min": 0.574351}, "location": {"width": 795, "top": 220, "height": 26, "left": 241}, "words": "胺过程中,有乳酸性酸中毒的报道(见【注意事项】,一般注意事项)。虽然上述报道主要出"}, {"probability": {"variance": 8.8e-05, "average": 0.995964, "min": 0.941307}, "location": {"width": 796, "top": 249, "height": 30, "left": 240}, "words": "现在应用利奈唑胺超过推荐的最长应用时间(28天)的患者中,但在用药时间较短的患者"}, {"probability": {"variance": 0.000972, "average": 0.989999, "min": 0.853351}, "location": {"width": 794, "top": 281, "height": 27, "left": 241}, "words": "中也有报道。利奈唑胺合用5-羟色胺类药物,包括抗抑郁药物如:选择性5-羟色胺再摄取"}, {"probability": {"variance": 0.00593, "average": 0.975393, "min": 0.601567}, "location": {"width": 784, "top": 310, "height": 30, "left": 242}, "words": "抑制剂(SSIs)的患者中,有5-羟色胺综合征的报告(见【注意事项】,一般注意事项)"}, {"probability": {"variance": 2.1e-05, "average": 0.997547, "min": 0.973106}, "location": {"width": 794, "top": 340, "height": 31, "left": 242}, "words": "在利奈唑胺应用的过程中有惊厥的报道(见【注意事项】,一般注意事项)。过敏性反应、血"}, {"probability": {"variance": 7.5e-05, "average": 0.99483, "min": 0.954031}, "location": {"width": 794, "top": 372, "height": 27, "left": 242}, "words": "管性水肿、描述为 Stevens Johnson综合征的皮肤水疱也有报道。曾有使用利奈唑胺后出现"}, {"probability": {"variance": 0.004914, "average": 0.987558, "min": 0.561217}, "location": {"width": 795, "top": 402, "height": 28, "left": 241}, "words": "牙齿和舌褪色的报道。在已知结果的病例中,牙齿褪色可以通过专业牙科清洁(手工除"}, {"probability": {"variance": 1.6e-05, "average": 0.998598, "min": 0.975621}, "location": {"width": 781, "top": 431, "height": 31, "left": 242}, "words": "垢)来清除。有低血糖包括症状发作的报道(见警告)。这些不良事件可能由于其严重性"}, {"probability": {"variance": 4.1e-05, "average": 0.997332, "min": 0.960057}, "location": {"width": 798, "top": 460, "height": 31, "left": 239}, "words": "报告的频度、与利奈唑胺可能的相关性,或同时伴有以上多种因素而被列出。由于上述事件"}, {"probability": {"variance": 6.4e-05, "average": 0.996866, "min": 0.957155}, "location": {"width": 794, "top": 491, "height": 27, "left": 243}, "words": "为自发性报告,无法知晓其来源于多大样本的患者人群,故不能对其发生率进行估计,也不"}, {"probability": {"variance": 0.002982, "average": 0.982641, "min": 0.779207}, "location": {"width": 307, "top": 520, "height": 29, "left": 245}, "words": "能准确地判定其与用药的因果关系"}, {"probability": {"variance": 4e-06, "average": 0.998584, "min": 0.995203}, "location": {"width": 70, "top": 583, "height": 25, "left": 250}, "words": "【禁忌】"}, {"probability": {"variance": 3.3e-05, "average": 0.996897, "min": 0.970586}, "location": {"width": 486, "top": 611, "height": 27, "left": 283}, "words": "本品禁用于已知对利奈唑胺或本品其他成分过敏的患者"}, {"probability": {"variance": 5.8e-05, "average": 0.994692, "min": 0.97916}, "location": {"width": 164, "top": 674, "height": 26, "left": 245}, "words": "单胺氧化酶抑制剂"}, {"probability": {"variance": 1.4e-05, "average": 0.997721, "min": 0.979136}, "location": {"width": 758, "top": 699, "height": 31, "left": 283}, "words": "正在使用任何能抑制单胺氧化酶A或B的药物(如:苯乙肼、异卡波肼)的患者,或两"}, {"probability": {"variance": 4.6e-05, "average": 0.996893, "min": 0.966745}, "location": {"width": 445, "top": 731, "height": 28, "left": 246}, "words": "周内曾经使用过这类药物的患者不应使用利奈唑胺"}, {"probability": {"variance": 4.8e-05, "average": 0.995863, "min": 0.976217}, "location": {"width": 269, "top": 792, "height": 28, "left": 245}, "words": "引起血压升高的潜在相互作用"}, {"probability": {"variance": 1.3e-05, "average": 0.996688, "min": 0.988055}, "location": {"width": 759, "top": 819, "height": 30, "left": 283}, "words": "除非能够对于患可能出现的血压升高进行监测,否则利奈唑胺不应用于高血压未控制"}, {"probability": {"variance": 0.000203, "average": 0.993061, "min": 0.931377}, "location": {"width": 798, "top": 846, "height": 37, "left": 246}, "words": "的患者、嗜铬细胞瘤、甲状腺机能亢进的患者和/或使用以下任何药物的患者:直接或间接"}, {"probability": {"variance": 2.3e-05, "average": 0.9966, "min": 0.976656}, "location": {"width": 796, "top": 881, "height": 29, "left": 246}, "words": "拟交感神经药物(如伪麻黄碱),血管加压药物(如:肾上腺素、去甲肾上腺素),多巴胺类"}, {"probability": {"variance": 0.003156, "average": 0.983529, "min": 0.695662}, "location": {"width": 613, "top": 911, "height": 31, "left": 247}, "words": "药物(如:多巴胺、多巴酚丁胺)(见【注意事项】、【药物相互作用】)"}, {"probability": {"variance": 0.006079, "average": 0.978138, "min": 0.676399}, "location": {"width": 312, "top": 974, "height": 28, "left": 248}, "words": "与5-羟色胺类药物潜在的相互作用"}, {"probability": {"variance": 0.003596, "average": 0.984231, "min": 0.622186}, "location": {"width": 756, "top": 999, "height": 34, "left": 287}, "words": "除非密切观察患者5-羟色胺综合征的体征和/或症状,否则利奈唑胺不应用于类癌综合"}, {"probability": {"variance": 0.000884, "average": 0.988604, "min": 0.839635}, "location": {"width": 794, "top": 1029, "height": 33, "left": 249}, "words": "征的患者和/或使用任何以下药物的患者:5-羟色胺再摄取抑制剂,三环类抗抑郁药,5-羟"}, {"probability": {"variance": 0.002988, "average": 0.983186, "min": 0.683955}, "location": {"width": 794, "top": 1060, "height": 32, "left": 249}, "words": "色胺5-HT1受体激动剂(曲普坦类药物)、哌替啶或丁螺环酮(见【注意事项】一般注意事"}, {"probability": {"variance": 0.000152, "average": 0.994267, "min": 0.955489}, "location": {"width": 206, "top": 1095, "height": 25, "left": 249}, "words": "项和【药物相互作用】)"}, {"probability": {"variance": 1e-06, "average": 0.999239, "min": 0.996597}, "location": {"width": 111, "top": 1156, "height": 25, "left": 256}, "words": "【注意事项】"}, {"probability": {"variance": 2.8e-05, "average": 0.996988, "min": 0.973657}, "location": {"width": 753, "top": 1179, "height": 34, "left": 291}, "words": "为减少耐药细菌的产生,并确保本品和其他抗菌药物的疗效,利奈唑胺应该仅用于治疗"}, {"probability": {"variance": 3e-05, "average": 0.996059, "min": 0.982531}, "location": {"width": 484, "top": 1213, "height": 31, "left": 251}, "words": "或预防已经证实或者高度怀疑由细菌引起的感染性疾病"}, {"probability": {"variance": 7e-05, "average": 0.988643, "min": 0.980305}, "location": {"width": 43, "top": 1249, "height": 24, "left": 250}, "words": "警告"}, {"probability": {"variance": 0.001112, "average": 0.988626, "min": 0.797322}, "location": {"width": 756, "top": 1269, "height": 36, "left": 291}, "words": "在应用利奈唑胺的患者中有出现骨髓抑制的报道(包括贫血、白细胞减少、全血细胞"}, {"probability": {"variance": 0.000337, "average": 0.991085, "min": 0.91172}, "location": {"width": 794, "top": 1300, "height": 35, "left": 253}, "words": "减少和血小板减少)。在已知转归的病例中,停用利奈唑胺后血象指标可以上升并回复到治"}, {"probability": {"variance": 0.000286, "average": 0.991584, "min": 0.930316}, "location": {"width": 795, "top": 1329, "height": 36, "left": 252}, "words": "疗前的水平。对应用利奈唑胺的患者应每周进行全血细胞计数的检查,尤其是那些用药超"}, {"probability": {"variance": 1.2e-05, "average": 0.996822, "min": 0.985667}, "location": {"width": 795, "top": 1358, "height": 39, "left": 253}, "words": "过两周,或用药前已有骨髓抑制,或合并应用能导致发生骨髓抑制的其他药物,或患慢性"}, {"probability": {"variance": 6.8e-05, "average": 0.996892, "min": 0.948728}, "location": {"width": 796, "top": 1391, "height": 35, "left": 253}, "words": "感染既往或目前合并接受其他抗生素治疗的患者。对发生骨髓抑制或骨髓抑制发生恶化的"}, {"probability": {"variance": 0.000112, "average": 0.992384, "min": 0.960928}, "location": {"width": 266, "top": 1426, "height": 31, "left": 253}, "words": "患者应考虑停用利奈唑胺治疗"}, {"probability": {"variance": 0.000658, "average": 0.991723, "min": 0.844798}, "location": {"width": 742, "top": 1451, "height": 35, "left": 294}, "words": "在成年和未成年的狗和大鼠中,曾观察到骨髓抑制、脾脏和肝脏的髓外血细胞生成减少"}, {"probability": {"variance": 8.9e-05, "average": 0.99485, "min": 0.970971}, "location": {"width": 135, "top": 1485, "height": 24, "left": 586}, "words": "第9页,共25页"}, {"probability": {"variance": 0.001642, "average": 0.971873, "min": 0.880809}, "location": {"width": 89, "top": 1512, "height": 22, "left": 314}, "words": "No:2013082"}], "language": 3}